TRK Inhibitors: Clinical Development of Larotrectinib
- 39 Downloads
Purpose of Review
In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.
The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. NTRK chromosomal alterations, most commonly gene fusions, have been identified as driver mutations in a broad range of malignancies. Small molecule tyrosine kinase inhibitors of Trk, including larotrectinib, have shown broad clinical activity across multiple tumor types with NTRK fusion events.
Although the prevalence of NTRK alterations is low, the exceptional activity of larotrectinib makes NTRK alterations an important predictive biomarker to screen for in any cancer.
KeywordsNTRK TRK inhibitor Larotrectinib Precision medicine Personalized medicine Targeted oncology
Compliance with Ethical Standards
Conflict of Interest
Munveer S. Bhangoo declares that he has no conflict of interest.
Darren Sigal has a patent issued on a method of treating neuroendocrine tumors.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24(23):5807–14.Google Scholar
- 16.Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, et al. Comprehensive genomic profiling identified novel NTRK fusions in neuroendocrine tumors. Oncotarget. 2018;9(88):35809–12.Google Scholar
- 18.Chen Y, Chi P. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 2018 7 [cited 2018 Aug 28];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992878/
- 19.• Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, et al. Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer. J Natl Compr Cancer Netw. 2017;15(11):1317–22 This paper highlights the utility of NTRK inhibition in a patient with metastatic neuroendocrine tumor, a tumor type not previously known to exhibit targetable driver mutations. CrossRefGoogle Scholar
- 21.• Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–76 This report characterizes the molecular pathogenesis of a secretory breast carcinoma, a rare histologic subtype associated with a TRK fusion event. CrossRefGoogle Scholar
- 22.Watanabe N, Kobayashi H, Hirama T, Kikuta A, Koizumi S, Tsuru T, et al. Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11: fluorescence in situ hybridization and IGF2 allelic expression analysis. Cancer Genet Cytogenet. 2002;136(1):10–6.CrossRefGoogle Scholar
- 29.Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, et al. Biallelic deletion of PALB2 occurs across multiple tumor types and suggests responsiveness to poly (ADP-ribose) polymerase inhibition. JCO Precis Oncol. 2017;1:1–7.Google Scholar
- 30.Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, et al. Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma. JCO Precis Oncol. 2017. https://doi.org/10.1200/PO.17.00034.
- 34.DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, et al. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018;124(21):4241–7.Google Scholar
- 35.•• Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9 Landmark study reporting the safety and efficacy results of three early-phase clinical trials utilizing larotrectinib across multiple tumor types (pediatric and adults). CrossRefGoogle Scholar
- 39.Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–47.Google Scholar
- 40.•• Benayed R, Offin MD, Mullaney KA, Sukhadia P, Rios KM, Desmeules P, et al. Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays. J Clin Oncol. 2018;36(15_suppl):12076 This study emphasizes the sensitivity of RNA sequencing techniques which may identify TRK fusions not seen with conventional DNA sequencing. CrossRefGoogle Scholar